PRX-08066 is a drug discovered and developed by Predix (later Epix) Pharmaceuticals [Dale S. Dhanoa et al. Patent US 7030240 B2] which acts as a potent and selective antagonist at the serotonin 5-HT2B receptor with a 5-HT2B binding affinity (Ki) of 3.4nM and high selectivity over the closely related 5-HT2A and 5-HT2C receptors and other receptor targets.
This page contains content from the copyrighted Wikipedia article "PRX-08066"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
